BackBellerophon Therapeutics Overview

Bellerophon Therapeutics Other Current Liabilities

Latest other current liabilities for BLPH: $640K.

Get informed when a big investor buys or sells

+ Follow
Other Current Liabilities
$644000.00
↓ 80.23% YoYΔ $-2.61M vs prior year quarter

Peer trimmed avg / median

Loading

Bellerophon Therapeutics Other Current Liabilities History

Loading

Bellerophon Therapeutics vs. peers: Other Current Liabilities Comparison

Loading

Bellerophon Therapeutics Other Current Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Bellerophon Therapeutics (BLPH) FAQ

Bellerophon Therapeutics's other current liabilities stands at $640K as of September 2023. That compares with $3.3M in the prior-year period — down 80.2% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.

Bellerophon Therapeutics reported $640K in other current liabilities versus $3.3M a year earlier — a 80.2% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.

That compares with $3.3M in the prior-year period — down 80.2% year over year. Sustained growth in other current liabilities can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.

The history chart shows how Bellerophon Therapeutics's other current liabilities evolved across reporting periods, while the comparison chart places BLPH next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.

Yes — within Healthcare, other current liabilities is commonly used to spot outliers. Bellerophon Therapeutics's reading of $640K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.